Radioembolization with angiotensin II to boost tumor radiation dose
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a drug called angiotensin II (which tightens blood vessels in healthy tissue) during radioembolization can deliver more radiation directly to liver tumors. It is for people who have liver tumors (either primary or that have spread to the liver) and are scheduled for radioembolization.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a liver tumor (either starting in the liver or spread from another part of the body).
- Your doctor has recommended a treatment called radioembolization (tiny radioactive beads are delivered into the liver's blood supply).
- Your liver tumor(s) are at least 2 centimeters in size.
- You are 18 years or older.
- You are not currently taking certain blood pressure medications (ACE inhibitors or ARBs), and you do not have poorly controlled high blood pressure.
- You have not had a stroke, blood clot, or mini-stroke in the past 6 months and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving targeted radiation after a liver procedure called trans-arterial chemoembolization for hepatocellular carcinoma (HCC). It may help control the cancer in people who cannot have surgery or transplant.
This trial tests a treatment called yttrium-90 radioembolization (tiny radioactive beads delivered to the liver) for people with liver cancer that has already been treated before. The goal is to see if it can help control the tumor when other treatments haven't been enough.
This trial tests combining radiation therapy (radioembolization) with surgery to remove part of the liver for people with a single large liver tumor (over 8 cm) that hasn't spread. The goal is to see if this approach can treat the tumor effectively.
This study tests a targeted radiation treatment called Y90 for liver tumors that are too large for standard approaches. It aims to see how well the treatment works for people with primary or secondary liver cancers that mainly affect the liver and have at least one tumor bigger than 5 cm.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
This trial combines three treatments: Y-90 radioembolization (targeted radiation to liver tumors), two immunotherapy drugs (durvalumab and tremelimumab), and a targeted oral drug (zanzalintinib) to see if this combination can shrink or control liver cancer that cannot be removed by surgery or transplant. It may be an option for people whose cancer has not spread beyond the liver and who have not had prior systemic treatment.
Hear when a new Liver Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.